Pharmacokinetic and pharmacodynamic properties of docetaxel: Results of phase I and phase II trials

American Journal of Health-System Pharmacy

Volumn 54, Issue SUPPL. 2, 1997, Pages

  Bruno, R ^a   Riva, A ^a   Hille, D ^a   Lebecq, A ^a   Thomas, L ^a  

^a SANOFI   (France)

Author keywords

Antineoplastic agents; Clinical studies; Docetaxel; Dosage; Excretion; Liver diseases; Pharmacodynamics; Pharmacokinetics; Surface area; Toxicity

Indexed keywords

DEXAMETHASONE; DOCETAXEL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESISTANCE; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DOSE LIVER FUNCTION RELATION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS;

EID: 0031471976     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.suppl_2.s16     Document Type: Conference Paper

References (14)

1. Mangatal L, Adeline MT, Guênard D et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron. 1989; 45:177-90.
2. Extra JM, Rousseau F, Bruno R et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993; 53:1037-42.
3. Bissett D, Setanoians A, Cassidy J et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 1993; 53:523-7.
4. Pazdur R, Newman RA, Newman BM et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst. 1992; 84:1781-8.
5. Burris H, Irvin R, Kuhn J et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993; 11:950-8.
6. Tomiak E, Piccart M, Kerger S et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994; 12:1458-67.
7. Taguchi T, Fume H, Niltani H et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Jpn J Cancer Chemother. 1994; 21:1997-2005.
8. Bruno R, Hille D, Vivier N et al. Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel in Phase II studies. J Clin Oncol. In press.
9. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM user's guide, parts I-IV. San Francisco: University of California; 1988-1990.
10. Bruno R, Mille D, Thomas L et al. Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere) in Phase II studies. Proc Am Soc Clin Oncol. 1995; 14. Abstract 1471.
11. Bruno R, Vivier N, Vergniol JC et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996; 24(2):153-72.
12. Oulid-Aissa D, Bruno R, Lebecq A et al. Taxotere safety in patients with impaired liver function. Proc Am Soc Clin Oncol. 1996; 15. Abstract 1508.
13. Burris HA. Optimal use of docetaxel (Taxotere): maximising its potential. Anticancer Drugs. 1996; 7(suppl 2):25-8.
14. Proc Am Soc Clin Oncol. 1997; 16. Abstract 770.